1 / 18

Bioeconomy Platforms, Distributed Knowledge & Related Variety

Bioeconomy Platforms, Distributed Knowledge & Related Variety. Phil Cooke Centre for Advanced Studies Cardiff University. As first a UK study, a postal questionnaire survey of medical genomics biotechnology firms – 20% RR Identification of UK bioregions Identification of global bioregions

reece
Download Presentation

Bioeconomy Platforms, Distributed Knowledge & Related Variety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bioeconomy Platforms, Distributed Knowledge & Related Variety Phil Cooke Centre for Advanced Studies Cardiff University

  2. As first a UK study, a postal questionnaire survey of medical genomics biotechnology firms – 20% RR Identification of UK bioregions Identification of global bioregions A scientometric mapping of co-publishing activities among ‘star’ bioscientists in global bioregions Interviews with UK survey respondents Analysis of public and private genomic markets Methods

  3. Age R&D/T mean – 21% (’02) <1989 (66) Patents – 47% respondents 1990-1995 (17) Mean Patents - 5 1996-2000 (56) Collaborations – 77% 2001- (17) Clustering – 78% Turnover Co-op Inno – 70% 1999 £900 m. Co-op Reg. – 18% 2003 £1,726 m. Co-op UK – 23% Co-op EU – 18% Co-op Global -28% Indicators

  4. R&D Co-operation Aims: New Product to Market – 86% Develop Patent – 71% New/Improved Product to Firm – 57% R&D Cooperations Highlights: Top Regional R&D Partner – University (30%) Top UK R&D Partner – University (43%) Top EU R&D Partner – Customer/Supplier (30%) Top N. American R&D Partner – Customer (35%) Top Asian & RoW R&D Partner – Customer (13%/8%) Indicators – R&D Co-operations

  5. Hepsera out-license Gilead Sciences GlaxoSmithKline Institute for Medical Research Gateway Fund Vistide out-license (joint venture) Pfizer Cambridge Biotechnology Addenbrooke’s Hospital Founders came out of Pfizer Neurodegeneration Consortium macrolide templates (funding) Biotica Northern Venture Managers Cambridge University Daniolabs (funding) Challenge Fund Babraham Bioscience Inst Technologies Ltd Wellcome Trust (Cambridge University administered) Lorantis (funding) Domantis Babraham Bioincubator Genzyme partnership Abbott Babraham Technix antibodies license Astex Cambridge Antibody Technology arthritis collaboration Cambridge Crytallographic Data Centre Eli Lilly validation licensing virtual screening collaboration Wyeth Amgen AstraZeneca (Cambridge University) licensing

  6. Core Biotechnology Clusters Comparative US and European Performance Indicators

  7. Global Bioscience Publication Shares

  8. Publishing Collaborations: Top 4 US Bioscience Journals

  9. Publishing Collaborations: Top 5 European Bioscience Journals

  10. Main Global Bioscience Co-publications

  11. 1992-2002 biochemistry & molecular biology most cited US & EU patent fields >46%. Pharmaceuticals firms outsourced 30% 2003 R&D budgets. Reached 50% by 2005, expected 2010 Bioregions co-publish with each other and leading bioregions dominate a global innovation system No longer dominated by corporate in-house R&D Bioscience Led The Way

  12. Open innovation (Chesbrough, 2003) Philips ‘Sense & Simplicity’ rebranding, R&D strategy based on ‘open innovation’ Cisco & Microsoft practise ‘open innovation’ through acquisition Dupont closed its central laboratories Lucent, IBM practise ‘open innovation’ German auto industry now managed by Frankfurt design & engineering consultancies Procter & Gamble/Gillette funded by ‘C&D’ open innovation Now Others Follow

  13. US Industrial R&D Outsourcing 1981-2001

  14. Genomic Medical Biotechnology is conducted in many new or pre-existing biotechnology firms Geographical Clustering in Bioregional Innovation Systems is Normal Global Research and Publication Linkages are Strong Among ‘Stars’ in Centres of Excellence R&D Outsourcing of R&D by Pharma is now 50% Reconfiguration of Global Economic Geography Dynamism Genomic Medical Biotechnology an Industrial Emulation Model Interim Conclusions

  15. A generalised theoretical framework for knowledge driven economic development

  16. Some cross-sector ‘platform’ candidate innovation biographies in firms & regions arising from WP3

  17. Firm Level Innovation Biographies

  18. Clusters are research and innovation in proximity but distant networks key also, US clusters dominate global biotechnology, Similar, though less scale, in Europe, Some European highlights, US clusters have more resources, including public and private (VC & pharma) investment, Notice how biotechnology, even biopharma is a far bigger ‘platform’ than is generally assumed Then notice how its platform character attracts innovators from distant sector spaces. Conclusions

More Related